Mitapivat-Pyrukynd in the treatment of thalassemia

Thalassemia is a common hereditary anemia disease that usually requires lifelong blood transfusions. As a new treatment drug, mitapivat-Pyrukynd has demonstrated significant efficacy in patients with non-transfusion-dependent thalassemia (NTDT). The mechanism of action of Metapival is to promote the normal metabolism of red blood cells by activating pyruvate kinase (PK-R), thus improving the symptoms of anemia.

In the treatment of thalassemia, the mechanism of action of metapival is similar to its mechanism in the treatment of anemia caused by pyruvate kinase deficiency. People with thalassemia often develop anemia due to abnormal red blood cell production or a shortened lifespan of red blood cells. Metapival activates the unique pyruvate kinase of red blood cells, promotes the energy production of red blood cells, enhances their survival ability, and thereby relieves anemia symptoms.

According to data from an open-label, multicenter, Phase 2 study, mitapival showed promising results in the treatment of adult patients with non-transfusion-dependent thalassemia. Research results show that metapival can effectively increase hemoglobin levels in these patients, reduce the production of ineffective red blood cells, and significantly improve anemia. In addition, the therapeutic effect of mitapival has been demonstrated in patients with different types of thalassemia, including patients with α-thalassemia and β-thalassemia.

Metapival can not only improve patients' blood indicators, but also improve their quality of life. For those patients with thalassemia who rely on long-term blood transfusions, mitapival offers a new treatment option that has the potential to reduce the need for blood transfusions, reduce treatment costs, and improve patients' quality of life.

Overall, metapival shows great potential in the treatment of thalassemia. By activating pyruvate kinase, Metapival can effectively relieve anemia symptoms, improve patients' blood parameters, and improve patients' quality of life.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/pyrukynd